Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT ID: NCT02022722

Last Updated: 2013-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate which treatment option for pelvic floor pain allows for improved sexual function.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pelvic floor pain may be treated with trigger point injections with medications (steroids and local anesthetics) that are FDA approved for injection into muscles. The alternative is a noninvasive treatment option using pelvic rehabilitation which involves vaginal muscle massage. Both treatment options have been used and reported; however, rapidity of improvement and return to normal sexual function have not been assessed. This study assigns patients to either treatment option randomly and the sexual function is assessed based on standardized sexual function questionnaires as well as pain ratings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspareunia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pelvic Floor Myalgia Trigger Point Injections Pelvic Rehabilitation Dyspareunia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pelvic Rehabilitation

Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks

Group Type ACTIVE_COMPARATOR

Pelvic Rehabilitation

Intervention Type PROCEDURE

Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy

Trigger Point Injections

Trigger point injections will be administered on weekly basis for a total of 6 weeks

Group Type ACTIVE_COMPARATOR

Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride

Intervention Type DRUG

The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride

The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.

Intervention Type DRUG

Pelvic Rehabilitation

Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Triamcinolone Acetonide-Total dose of 40mg, Volume 2 ml Bupivacaine Hydrochloride-Strength 0.5%, Volume 18ml Pelvic floor massage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pelvic pain
* pelvic floor myalgia
* dyspareunia
* female
* age \> 18 years

Exclusion Criteria

* interstitial cystitis
* vaginal lesions / ulcerations
* prior trigger point injections in the past 6 months
* prior pelvic rehabilitation in the past 6 months
* laparoscopically documented endometriosis / pelvic adhesions or adhesive disease
* documented pelvic inflammatory disease identified within the past 6 months
* documented sexually transmitted disease within the past 6 months
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Patty Brisben Foundation For Women's Sexual Health

OTHER

Sponsor Role collaborator

University of Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mary South

MD, Director of Female Pelvic Medicine & Reconstructive Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mary South, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Urogynecology, University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dani Zoorob, MD

Role: CONTACT

Phone: 5135629080

Email: [email protected]

Mary South, MD

Role: CONTACT

Phone: 5135629080

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dani Zoorob, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996 Mar;87(3):321-7. doi: 10.1016/0029-7844(95)00458-0.

Reference Type BACKGROUND
PMID: 8598948 (View on PubMed)

Rao SS, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009 May 1;29(9):985-91. doi: 10.1111/j.1365-2036.2009.03964.x. Epub 2009 Feb 13.

Reference Type RESULT
PMID: 19222415 (View on PubMed)

Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26(1):59-62. doi: 10.1002/nau.20393.

Reference Type RESULT
PMID: 17195176 (View on PubMed)

Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):46-50. doi: 10.1111/j.1479-828X.2004.00163.x.

Reference Type RESULT
PMID: 15089868 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Patty Brisben Foundation

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

UC IRB Study #: 2013-0677

Identifier Type: -

Identifier Source: org_study_id